Breast Cancer
Conditions
Keywords
breast cancer, breast-conserving surgery, radiotherapy, mastectomy
Brief summary
The optimal surgical treatment option (BCS+RT versus MAST) for young patients with early-stage breast cancer remains debated. The present study aims to explore trends in surgical management and compare survival outcomes between BCS+RT and MAST in young patients with early-stage breast cancer, ultimately providing optimal treatment strategies for Asian populations.
Detailed description
This study is a unique addition to the current research on young women with early-stage breast cancer, aiming to compare the survival outcomes between BCS+RT and MAST, providing valuable insights into their effectiveness for this group of patients. This study enrolled patients at West China Hospital, Sichuan University. Kaplan-Meier analyses with the log-rank test were applied to compare the locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), breast cancer-specific survival (BCSS), and overall survival (OS). Cox multivariate hazard regression was employed to assess hazard ratios (HRs) between the two groups for survival outcomes.
Interventions
PROCEDUREMAST group
PROCEDUREbreast-conserving surgery plus adjuvant radiotherapy
Patients with early-stage (stage I, stage II, T≤2), and having the willingness to receive BCS were treated with BCS. All patients with BCS received post-surgery radiotherapy. Radiotherapy was administrated with a prescribed dose of 40 Gy in 15 fractions with photons and a boost of 10-16 Gy in 5-8 fractions with electrons to the ipsilateral breast. If axillary lymph nodes were involved, a conventional fraction was delivered with a prescribed dose of 50 Gy in 25 fractions to the ipsilateral breast and draining lymph node regions.
Sponsors
West China Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged 18-40 years. * Pathological diagnosis of invasive breast cancer. * Undergoing Breast-Conserving Surgery (BCS) with Radiotherapy (RT) or Mastectomy (MAST). * Availability of detailed clinical information, including: Tumor (T) stage. Node (N) stage. Clinical stage. Hormone receptor status. Endocrine therapy details. Targeted therapy details.
Exclusion criteria
* Male patients. * Patients with distant metastatic disease. * Patients with bilateral breast cancer. * Patients not undergoing surgery. * Follow-up time of less than 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Breast cancer-specific survival (BCSS) | Jan 1, 2008 to 31 Dec, 2019 |
| LRFS (Locoregional Recurrence-Free Survival) | Jan 1, 2008 to 31 Dec, 2019 |
| DMFS (Distant Metastasis-Free Survival) | Jan 1, 2008 to 31 Dec, 2019 |
| OS (Overall Survival) | Jan 1, 2008 to 31 Dec, 2019 |
Outcome results
None listed